DEL MASTRO L

No description

No description

Temporary ovarian suppression with gonadotropin‐releasing hormone agonist during chemotherapy might be a reliable strategy not only to preserve ovarian function but also to increase the likelihood of becoming pregnant after the end of cytotoxic therapy. The findings of Blumenfeld et al. are consistent with recent data suggesting the efficacy of...

No description

Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomised study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31(9), 1157-1163 (2013). The introduction of trastuzumab in the treatment of HER-2-positive metastatic breast...

No description

No description

Granulocyte-colony stimulating factors (G-CSFs) are commonly employed in clinical practice. The most relevant adverse event of G-CSF administration is bone pain. Approximately 20% of cancer patients experienced bone pain with the administration of prophylactic daily G-CSFs (lenograstim and filgrastim). The reported incidence of bone pain in...

No description

No description

Background: Breast cancer is composed of distinct subtypes defined mainly based on the expression of hormone receptors (HR) and HER2. For years, reproductive factors were shown to impact breast cancer risk but it is unclear whether this differs according to tumor subtype. In this meta-analysis we evaluated the association between parity, age at...

Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5years has been for a long time the standard of care, as it is associated with overall positive clinical outcomes. However, in the last...

No description

Lapatinib is able to penetrate brain metastases from HER2-positive breast cancer. We assessed lapatinib concentration in cerebrospinal fluid (CSF) of two patients with HER2-positive metastatic breast cancer and brain metastases, and we found low levels of the drug in CSF of both patients. Lapatinib concentration in CSF may not be a reliable...